Search
Innoviva Inc
INVAAdd to Watchlist
21.995USD
+0.095+0.43%
Market hours （ET）Quotes delayed by 15 min
1.62BMarket Cap
3.02P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.27%
5 Days
-7.11%
1 Month
+2.09%
6 Months
+9.85%
Year to Date
+9.85%
1 Year
+10.96%
Key Figures
22.050Open
22.070High
48.63KVolume
3.02P/E TTM
9.12P/E Dynamic
--Dividend TTM
0.07%Turnover Ratio
21.900Prev. Close
21.700Low
705.54KTurnover
69.40P/E Static
1.21P/B
0.00%Div Yield TTM
32.63%ROA
25.14552wk High
0.31Volume Ratio
23.39MNet Profit
73.81MShares
7.2825EPS TTM
0.36Beta
50.72%ROE
16.52052wk Low
1.69%Amplitude
77.39%Gross Margin
1.62BMarket Cap
1.60Reward/Risk
1.61%Risk Rate
TradingKey Stock Score of Innoviva Inc
Currency: USD Updated: 2026-07-01Key Insights
Innoviva Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 30 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 35.50.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Innoviva Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Innoviva Inc Highlights
StrengthsRisks
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 32.49% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 411.33M.
Undervalued
The company’s latest PE is 3.01, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 80.96M shares, decreasing 5.11% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 154.99K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.24.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
35.500
Target Price
+56.32%
Upside Space
Innoviva Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Innoviva Inc Info
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
Ticker SymbolINVA
CompanyInnoviva Inc
CEORaifeld (Pavel)
Websitehttps://www.inva.com/
Related Instruments
+1.98%
+1.46%
+4.04%
+1.53%
+1.92%
+2.98%
+2.21%
+3.70%
+2.11%
+1.84%
+3.62%
+2.58%
+3.25%
+2.65%
+1.45%
0.00%
+2.27%
+3.91%
+0.58%
+4.20%Popular Instruments
52703.900
+449.600 (+0.86%)
29852.300
+53.000 (+0.18%)
7525.700
+50.200 (+0.67%)
14846.000
-509.000 (-3.31%)
69069.000
-416.000 (-0.60%)
6374.200
+98.800 (+1.57%)
67.484
-0.484 (-0.71%)
303.365
+8.985 (+3.05%)
198.860
+1.280 (+0.65%)
4124.360
+93.590 (+2.32%)
FAQs
What is the current price of Innoviva Inc (INVA)?
The current price of Innoviva Inc (INVA) is 21.90.
What is the symbol of Innoviva Inc?
The ticker symbol of Innoviva Inc is INVA.
What is the 52-week high of Innoviva Inc?
The 52-week high of Innoviva Inc is 25.14.
What is the 52-week low of Innoviva Inc?
The 52-week low of Innoviva Inc is 16.52.
What is the market capitalization of Innoviva Inc?
The market capitalization of Innoviva Inc is 1.62B.
Is Innoviva Inc (INVA) currently rated as Buy, Hold, or Sell?
According to analysts, Innoviva Inc (INVA) has an overall rating of Buy, with a price target of 35.50.
What is the Earnings Per Share (EPS TTM) of Innoviva Inc (INVA)?
The Earnings Per Share (EPS TTM) of Innoviva Inc (INVA) is 4.02.